Dark

Check out our Dark Pool Levels

SESN
Sesen Bio, Inc. Common Stock
stock NASDAQ

Inactive

Mar 8, 2023

3.67USD+483.651%(+3.04)498,839

Pre-market

0.00USD-100.000%(-0.63)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 12, 2022

08:08AM EST Sesen Bio 8-K Shows FDA Granted Co. Request For Type C Meeting To Discuss Study Protocol For Added Phase 3 Trial Co. Will Conduct For Potential Resubmission Of Its Biologics License Application For Vicineum For Treatment Of Bladder Cancer Benzinga

08:08AM EST UPDATE: Sesen Says FDA Type C Meeting Scheduled For Mar. 28, 2022 Benzinga

Jan 10, 2022

08:00AM EST Sesen Bio Further Enhances Team with Key Hires Business Wire

Jan 6, 2022

08:04AM EST Sesen Bio 8-K Shows Co. To Receive $20M Milestone Payment Related To License Deal With F. Hoffman-La Roche Benzinga

Dec 9, 2021

09:46PM EST Sesen Bio Says Plans to Conduct Additional Trial For Potential Resubmission Of Vicineum BLA; Expects To Hold Type C Meeting With FDA Early 2022 Benzinga

08:18AM EST Sesen Bio Announces Regulatory Path Forward For Vicineum; Expects To Hold Type C Meeting With FDA In Early 2022 RTTNews

08:00AM EST Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum(tm) Business Wire

Nov 29, 2021

08:00AM EST Sesen Bio Strengthens Medical Team Business Wire

Nov 23, 2021

08:00AM EST Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role Business Wire

Nov 18, 2021

08:15AM EST Sesen Bio Says On Nov 17, FDA Granted Co. Request For A Type A Meeting To Discuss Recommendations Regarding CRL For Co.'s BLA For Vicineumtm; Clinical Type A Meeting Scheduled For December 8, 2021 Benzinga

Nov 8, 2021

08:11AM EST Sesen Bio Q3 EPS $0.36 Up From $(0.19) YoY Benzinga

08:07AM EST Sesen Bio Q3 EPS $0.36 Vs. Loss/shr $0.19 Last Year RTTNews

08:00AM EST Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update Business Wire

Nov 1, 2021

08:09AM EDT Sesen Bio Announces Productive CMC Type A Meeting With The FDA RTTNews

08:01AM EDT Sesen Bio Announces Type A Meeting With FDA; Co. Says It 'believes it has a clear understanding of what additional information regarding CMC is required for resubmission of the BLA.' Benzinga

08:00AM EDT Sesen Bio Announces Productive CMC Type A Meeting with the FDA Business Wire

Oct 25, 2021

07:00AM EDT The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.25 A.M. EDT). RTTNews

Oct 22, 2021

06:10AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.50 A.M. EDT). RTTNews

Oct 21, 2021

12:10PM EDT Mid-Afternoon Market Update: Nasdaq Turns Lower; Sesen Bio Shares Surge Benzinga

06:17AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.05 A.M. EDT). RTTNews

Oct 20, 2021

12:18PM EDT Mid-Day Market Update: Healthcare Services Drops After Q3 Results; Radius Health Shares Jump Benzinga

08:16AM EDT The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review Benzinga

06:28AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.00 A.M. EDT). RTTNews

Oct 19, 2021

05:16PM EDT Why Sesen Bio Stock Is Trading Higher Higher During Tuesday's After-Hours Session Benzinga

04:11PM EDT Sesen Bio 8-K Shows FDA Granted Co. Request For Type A Meeting To Discuss Issues Raised In FDA's Complete Response Letter Related To Vicineum Benzinga

Oct 17, 2021

04:00PM EDT Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Sesen Bio, Inc. - SESN PR Newswire

Oct 15, 2021

10:50PM EDT SESEN BIO 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Sesen Bio, Inc. - SESN Business Wire

Oct 14, 2021

10:06AM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

Oct 13, 2021

10:28PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Oct 12, 2021

10:50PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

08:13AM EDT Sesen Bio Says Welcomes Eun And Chrie O Further Strengthen capabilities Across CMC And Clinical Teams RTTNews

08:00AM EDT Sesen Bio Expands CMC and Clinical Teams Business Wire

Oct 11, 2021

10:26PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

04:14PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Oct 9, 2021

12:05PM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

Oct 8, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Oct 5, 2021

11:24PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

Oct 4, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

03:26PM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

Oct 1, 2021

10:50PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Sep 29, 2021

09:39PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Sep 28, 2021

10:25PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

09:33AM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

Sep 27, 2021

10:54PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Sep 24, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Sep 23, 2021

07:38PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

04:38PM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

Sep 21, 2021

10:32PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

Sep 20, 2021

10:48PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Sep 18, 2021

11:24AM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

Sep 17, 2021

10:00PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Sep 15, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Sep 14, 2021

10:50PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

Sep 13, 2021

03:16PM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

10:00AM EDT SESN, GNRC & PYPL - Bronstein, Gewirtz & Grossman, LLC Reminds GlobeNewswire Inc

Sep 10, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

07:36PM EDT Sesen Bio Shares Spike Higher; Co Issues 8K Filing Saying Preliminary Results From Interim Analysis Of 12 Patients In NCI Trial Being Presented Benzinga

Sep 9, 2021

06:38PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Sep 8, 2021

09:42PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Sep 7, 2021

10:40PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

01:44PM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

Sep 6, 2021

10:23PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Aug 31, 2021

11:02PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

10:17PM EDT Pomerantz Law Firm Announces the Filing of a Class Action Against Sesen Bio, PR Newswire

Aug 30, 2021

10:50PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

02:23PM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

Aug 27, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Aug 25, 2021

10:27PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

12:05PM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

Aug 24, 2021

09:36AM EDT Investors to Filing of Securities Fraud Class Action, Encourages Investors with $250K+ Losses to Contact Firm's Attorneys Now PR Newswire

Aug 20, 2021

08:00PM EDT SESEN BIO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Sesen Bio, Inc. and Encourages Investors to Contact the Firm Business Wire

07:45PM EDT Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. GlobeNewswire Inc

12:30PM EDT Gainey McKenna & Egleston Announces A Class Action Lawsuit Has GlobeNewswire Inc

Aug 19, 2021

09:10PM EDT SESEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Sesen Bio, Inc. on Behalf of Sesen Stockholders and Encourages Investors to Contact the Firm Business Wire

01:31PM EDT Securities Fraud Claims on Behalf of Sesen Bio, Inc. (NASDAQ: SESN) Investors PR Newswire

06:01AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 5.30 A.M. EDT). RTTNews

Aug 18, 2021

05:57AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 5.32 A.M. EDT). RTTNews

Aug 16, 2021

02:32PM EDT Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet Benzinga

12:13PM EDT Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump Benzinga

10:50AM EDT Sesen Bio, Inc. (SESN) shares are falling on Monday morning trade after the FDA determined that it cannot approve the BLA for Vicineum in its present form and has provided additional clinical/statistical data recommendations in addition to chemistry, manufacturing, and controls issues. RTTNews

10:34AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2021 Benzinga

10:22AM EDT Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August Benzinga

06:31AM EDT HC Wainwright & Co. Downgrades Sesen Bio to Neutral Benzinga

Aug 15, 2021

12:16PM EDT The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow Benzinga

11:06AM EDT The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow Benzinga

Aug 13, 2021

02:43PM EDT UPDATE: Sesen Bio Says 'FDA has determined that it cannot approve the BLA for Vicineum in its present form' Benzinga

02:40PM EDT Sesen Bio Receives Complete Response Letter from FDA for Vicineum (oportuzumab monatox-qqrs) Benzinga

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 11, 2021

08:04AM EDT Sesen Bio Appoints John Knighton Vice President and Chief Compliance Officer Benzinga

08:00AM EDT Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum(tm) Business Wire

Aug 10, 2021

02:42PM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

Aug 9, 2021

07:31AM EDT Sesen Bio Believes it Remains On Rrack for an FDA Decision on its BLA for Vicineum by August 18, 2021 Benzinga

07:15AM EDT Sesen Bio Q2 Loss/shr Narrows To $0.15 From $0.24 Last Year RTTNews

07:00AM EDT Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum(tm) Business Wire

Aug 5, 2021

08:20AM EDT Sesen Bio Announces Partnership With Eczacibasi Pharma Marketing for Commercialization Of Vicineum In Turkey RTTNews

08:16AM EDT Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing for the Commercialization of Vicineum in Turkey; Sesen Bio To Receive $1.5M Upfront And Is Eligible For Additional Regulatory And Commercial Milestone Payments Benzinga

08:00AM EDT Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum(tm) in Turkey Business Wire

Aug 2, 2021

06:10PM EDT Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates Benzinga

08:09AM EDT Sesen Bio Appoints Amy Ponpipom As VP Assistant General Counsel RTTNews

08:00AM EDT Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum(tm) Business Wire

Jul 26, 2021

08:06AM EDT Sesen Bio Says Has Completed Its Commercial Build Phase In Preparation For The Anticipated Launch Of Vicineum Benzinga

08:00AM EDT Sesen Bio Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum(tm) in the US Business Wire

Jul 21, 2021

08:00AM EDT Sesen Bio Announces New Appointments to its Board of Directors Business Wire

Jul 20, 2021

09:45AM EDT Sesen Bio And Qilu Pharmaceutical Announce Enrollment Of First Patient In Clinical Trial For Vicineum In China RTTNews

09:43AM EDT Sesen Bio, Qilu Pharmaceutical Announce Enrollment Of First Patient In Clinical Trial For Vicineum In China Benzinga

09:42AM EDT Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum(tm) in China Business Wire

Jul 14, 2021

08:59AM EDT Sesen Bio Announces Positive Outcome From Late-Cycle FDA Meeting For Vicineum Application Benzinga

08:44AM EDT Sesen Bio Files Prospectus For Open Market Sale Agreement For Up To $100M Shares Of Common Stock Benzinga

08:22AM EDT Sesen Bio Announces Productive Late-Cycle Meeting With The FDA For Vicineum(tm) RTTNews

08:15AM EDT Sesen Bio Announces Jul. 13 Late-Cycle Meeting With FDA For Vicineum; Says No Advisory Committee Meeting Planned At This Time, Remains On Track For Aug. 18 Target PDUFA Date Benzinga

08:00AM EDT Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum(tm) Business Wire

Jul 2, 2021

08:04AM EDT Sesen Bio Reports Inducement Grants Under Nasdaq Listing Rule RTTNews

08:00AM EDT Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Jun 30, 2021

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 22, 2021

08:22AM EDT Cramer Shares His Thoughts On Sesen Bio, Marathon Oil, More Benzinga

Jun 18, 2021

08:05AM EDT Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RTTNews

07:46AM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

Jun 15, 2021

11:34AM EDT Sesen Bio Option Alert: Aug 20 $4 Calls Sweep (12) near the Ask: 805 @ $1.25 vs 5258 OI; Earnings 8/9 Before Open [est] Ref=$4.145 Benzinga

08:07AM EDT The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda Benzinga

Jun 10, 2021

08:13AM EDT The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal Benzinga

Jun 9, 2021

09:14AM EDT The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US Benzinga

Jun 8, 2021

09:17AM EDT The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex Benzinga

08:12AM EDT Sesen Bio 8-K Shows Co. Expected To Be Added To Russell 3000 Index, Effective At Market Open Jun. 28 Benzinga

Jun 3, 2021

08:23AM EDT The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout Benzinga

Jun 2, 2021

08:21AM EDT Sesen Bio Announces Global Supply Agreement For Vicineum With Qilu Pharmaceutical RTTNews

08:20AM EDT The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements Benzinga

08:10AM EDT Sesen Bio Reports Global Supply Partnership With Qilu Pharma; Co. Will Receive $2M Milestone Payment Upon Completion Of Technology Transfer Benzinga

08:00AM EDT Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical Business Wire

Jun 1, 2021

08:46AM EDT Sesen Bio Names Patricia Drake Chief Commercial Officer, Steve Barbera VP, Market Access RTTNews

08:00AM EDT Sesen Bio Strengthens Senior Leadership Team Business Wire

07:55AM EDT Sesen Bio Inc Says May Offer And Sell Shares Of Up To $100M Common Stock From Time To Time Benzinga

May 27, 2021

08:00AM EDT Dr. Thomas Cannell, President and CEO of Sesen Bio, to Participate in Fireside Chat at the 2021 Jefferies Virtual Healthcare Conference Business Wire

May 21, 2021

04:30PM EDT Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire

May 10, 2021

08:06AM EDT Sesen Bio Q1 Loss Per Share $0.35 Vs EPS $0.31 Last Year RTTNews

07:42AM EDT Sesen Bio Q1 EPS $(0.35) Misses $(0.08) Estimate Benzinga

07:30AM EDT Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum(tm) Business Wire

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 4, 2021

08:25AM EDT Sesen Bio Gives Vicineum Launch Update; Says Co Remains On Track For Potential Approval In U.S. In August 2021 Benzinga

08:00AM EDT Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum(tm) Business Wire

May 3, 2021

08:00AM EDT Sesen Bio to Host Conference Call to Review First Quarter 2021 Financial Results and Provide Business Update on Monday, May 10, 2021 Business Wire

Apr 16, 2021

04:30PM EDT Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Apr 8, 2021

08:55AM EDT Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity "Horizons in Oncology" Virtual Conference Business Wire

Apr 7, 2021

08:13AM EDT Sesen Bio Reports ISS, Glass, Lewis Recommend Co.'s Shareholders Vote FOR Proposal To Increase Number Of Shares By 200M Benzinga

08:00AM EDT Sesen Bio Announces Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend "FOR" Proposal to Increase Authorized Shares Business Wire

Apr 5, 2021

08:08AM EDT Sesen Bio Says As Of Mar. 31 Had ~$110M In Cash And Equivalents Benzinga

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

Mar 22, 2021

08:08AM EDT Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RTTNews

08:07AM EDT Sesen Bio And Qilu Pharma Announce Approval Of IND Application Of Vicineum In China RTTNews

08:05AM EDT Sesen Bio and Qilu Pharmaceutical Announce Approval of IND Application in China for Vicineum Benzinga

08:00AM EDT Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Mar 15, 2021

07:07AM EDT Sesen Bio Q4 Net Loss $15.0 Mln Or $0.11/Shr Vs Loss $33.6 Mln Or $0.32/Shr Last Year RTTNews

07:00AM EDT Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company's Lead Product Candidate Vicineum(tm) Business Wire

Mar 8, 2021

08:50AM EST Sesen Bio Submits Marketing Authorization Application To European Medicines Agency For Vicineum RTTNews

08:46AM EST Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum(tm) Business Wire

08:10AM EST Sesen Bio Submits Marketing Authorization Application To European Medicines Agency For Vicineum Benzinga

Mar 2, 2021

08:00AM EST Sesen Bio Announces Conference Call with Neal Shore, M.D., FACS to Provide Clinical Perspective on the Company's Lead Product Candidate Vicineum(tm) Business Wire

Feb 17, 2021

10:18AM EST Canaccord Genuity Maintains Buy on Sesen Bio, Raises Price Target to $7 Benzinga

09:12AM EST Sesen Bio Says Has Remaining Capacity To Sell Up To $35M Open Market Sale Agreement Benzinga

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

06:54AM EST HC Wainwright & Co. Maintains Buy on Sesen Bio, Raises Price Target to $8 Benzinga

Feb 16, 2021

09:13AM EST Sesen Bio's Vicineum US Application For Bladder Cancer Accepted For Review; Shares Spike Benzinga

07:20AM EST Sesen Bio Announces FDA Acceptance And Priority Review Of Its BLA For Vicineum RTTNews

07:03AM EST Sesen Bio Announces FDA Acceptance And Priority Review Of Its Biologics License Application For Vicineum Benzinga

Feb 12, 2021

04:30PM EST Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide a Business Update Business Wire

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Feb 1, 2021

08:03AM EST Sesen Bio Announces Successful Application Orientation Meeting With FDA For Vicineum Benzinga

08:00AM EST Sesen Bio Announces Successful Application Orientation Meeting (AOM) with the FDA for Vicineum(tm) Business Wire

Jan 27, 2021

07:36AM EST The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga

Jan 19, 2021

08:12AM EST Sesen Bio Says Completed Assessment Aid submission To FDA In Connection With Biologics License Application For Vicineum Benzinga

Jan 13, 2021

08:12AM EST Sesen Bio And Qilu Pharmaceutical Announce IND Application For Vicineum Accepted For Review By National Medical Products Administration In China; Sesen Bio To Receive $3M Milestone Payment Upon IND Approval Benzinga

08:10AM EST Sesen Bio And Qilu : IND Application For Vicineum Accepted For Review In China RTTNews

08:01AM EST Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum(tm) Accepted for Review by the National Medical Products Administration in China Business Wire

Jan 11, 2021

08:19AM EST Sesen Bio Inc Says It Had Cash, Cash Equivalents, And Restricted Cash Of About $55M As Of Dec 31, 2020 Benzinga

Dec 21, 2020

08:09AM EST Sesen Bio Announces Submission Of Completed BLA To FDA For Vicineum RTTNews

08:07AM EST Sesen Bio Submits a Biologics License Application to the FDA Benzinga

08:05AM EST Sesen Bio Submits Completed Biologics License Application To FDA For Vicineum, Has Requested Priority Review Benzinga

08:00AM EST Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum(tm) and Has Requested Priority Review Business Wire

Dec 18, 2020

08:00AM EST Sesen Bio Announces Positive Cost-Effectiveness Profile for Vicineum(tm) Based on the Final Evidence Report Issued by the Institute for Clinical and Economic Review (ICER) Business Wire

Dec 17, 2020

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

Dec 16, 2020

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 7, 2020

08:06AM EST Sesen Bio Announces Commercial Manufacturing and Global Supply Partnership With Qilu Pharmaceutical; Sesen To Receive $2M Milestone Payment Upon Completion Of Technology Transfer Benzinga

08:00AM EST Sesen Bio Announces Commercial Manufacturing and Global Supply Partnership with Qilu Pharmaceutical Business Wire

Dec 1, 2020

08:12AM EST Sesen Bio Announces Partnership With Hikma Pharmaceuticals For The Commercialization Of Vicineum In The Middle East And North Africa Benzinga

08:09AM EST Sesen Bio Partners With Hikma Pharma For Commercialization Of Vicineum In Middle East And North Africa RTTNews

08:00AM EST Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum(tm) in the Middle East and North Africa Business Wire

Nov 9, 2020

07:41AM EST Sesen Bio Q3 EPS $(0.19) Misses $(0.08) Estimate, Sales $11.20M Benzinga

07:30AM EST Sesen Bio Reports Third Quarter 2020 Financial Results and Positive Progress Towards Completing the BLA Submission for VicineumTM in December 2020 Business Wire

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 2, 2020

08:00AM EST Sesen Bio to Host Conference Call to Review Third Quarter Financial Results and Provide an Update on Positive Progress Towards Demonstration of Analytical Comparability Business Wire

Oct 26, 2020

08:20AM EDT Sesen Bio Says Completes Successful Pre-submission Meeting With EMA For Vicineum1 For BCG-unresponsive NMIBC In Europe RTTNews

08:10AM EDT Sesen Bio Reports Successful Pre-Submission Meeting With European Medicines Agency For Vicineum Benzinga

08:00AM EDT Sesen Bio Announces Successful Pre-Submission Meeting with the European Medicines Agency for Vicineum(tm) Business Wire

Oct 19, 2020

08:02AM EDT Sensen Bio Announces Cardinal Health to Mange Distribution of Vicineum in the United States Benzinga

08:00AM EDT Sesen Bio Announces an Exclusive Agreement With Cardinal Health for Third-Party Logistics and Specialty Pharmaceutical Distribution Services for Vicineum(tm) Business Wire

Sep 8, 2020

07:00AM EDT Sesen Bio to Provide Business Update at the H. C. Wainwright 22nd Annual Global Investment Conference Business Wire

Aug 10, 2020

11:08AM EDT Sesen Bio shares are trading lower after the company reported worse-than-expected Q2 EPS results. UPDATE: Shares have reversed since then. Benzinga

07:49AM EDT Sesen Bio Q2 Net Loss $26.3 Mln Or $0.24/Shr Vs Net Loss Of $54.3 Mln Or $0.67/Shr Last Year RTTNews

07:46AM EDT Sesen Bio Q2 EPS $(0.24) Misses $(0.09) Estimate Benzinga

07:42AM EDT Sesen Bio Reports Second Quarter 2020 Financial Results and Business Update Business Wire

Aug 5, 2020

04:16PM EDT Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference Business Wire

Jul 31, 2020

07:38AM EDT Sesen Bio Announces Agreement With Qilu For Development And Commercialization Of Vicineum In China RTTNews

07:31AM EDT Sesen Bio Announces An Exclusive License Agreement With Qilu Pharmaceutical For The Development And Commercialization Of Vicineum In Greater China; Co. To Receive $12M Upfront And $23M In Potential Milestones Benzinga

07:30AM EDT Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum(tm) in Greater China Business Wire

Jul 30, 2020

08:01AM EDT Sesen Bio to Host Conference Call to Provide OUS Business Update Business Wire

Share